Search Results - "Hautefeuille, Vincent"

Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study by Salimon, Maëva, Prieux-Klotz, Caroline, Tougeron, David, Hautefeuille, Vincent, Caulet, Morgane, Gournay, Jérôme, Matysiak-Budnik, Tamara, Bennouna, Jaafar, Tiako Meyo, Manuela, Lecomte, Thierry, Zaanan, Aziz, Touchefeu, Yann

“…Background: Hepatocholangiocarcinoma (cHCC-ICC) is a rare liver tumour for which no data on chemosensitivity exist. The aims of this multicentre study were to…”
Get full text

Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study by Zaibet, Sonia, Hautefeuille, Vincent, Auclin, Edouard, Lièvre, Astrid, Tougeron, David, Sarabi, Mathieu, Gilabert, Marine, Wasselin, Julie, Edeline, Julien, Artru, Pascal, Bechade, Dominique, Morin, Clémence, Ducoulombier, Agnes, Taieb, Julien, Pernot, Simon

“…Background Gemcitabine (Gem) alone or with Nab-paclitaxel (Gem-Nab) is used as second-line treatment for metastatic pancreatic adenocarcinoma (mPA) after…”
Get full text

Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos) by Palazzo, Maxime, Napoléon, Bertrand, Gincul, Rodica, Pioche, Mathieu, Pujol, Bertrand, Lefort, Christine, Fumex, Fabien, Hautefeuille, Vincent, Fabre, Monique, Cros, Jérome, Felce, Michèle, Couvelard, Anne, Sauvanet, Alain, Lévy, Philippe, Ruszniewski, Philippe, Palazzo, Laurent

“…Contrast harmonic EUS (CH-EUS) has the ability to depict tumor microvasculature. Decreased microvascular density has been identified as a factor associated…”
Get full text

FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin by Hadoux, Julien, Afchain, Pauline, Walter, Thomas, Tougeron, David, Hautefeuille, Vincent, Monterymard, Carole, Lorgis, Véronique, Thuillier, Frédéric, Baudin, Eric, Scoazec, Jean Yves, Lepage, Côme, Desgrippes, Romain

“…Poorly differentiated neuroendocrine carcinomas (NEC) are rare diseases with a poor prognosis. Platinum-etoposide (PE) has been the recommended first-line…”
Get full text

Efficacy of treatments for VIPoma: A GTE multicentric series by Brugel, Mathias, Walter, Thomas, Goichot, Bernard, Smith, Denis, Lepage, Côme, Cao, Christine Do, Hautefeuille, Vincent, Rebours, Vinciane, Cadiot, Guillaume, de Mestier, Louis

“…Vasoactive intestinal peptide-secreting tumor (VIPoma) is a very rare, life-threatening, functioning pancreatic neuroendocrine tumor (pNET). The efficacy of…”
Get full text

Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study by Williet, Nicolas, Saint, Angélique, Pointet, Anne-Laure, Tougeron, David, Pernot, Simon, Pozet, Astrid, Bechade, Dominique, Trouilloud, Isabelle, Lourenco, Nelson, Hautefeuille, Vincent, Locher, Christophe, Desrame, Jérome, Artru, Pascal, Thirot Bidault, Anne, Le Roy, Bertrand, Pezet, Denis, Phelip, Jean-Marc, Taieb, Julien

“…Background: Folfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-line treatments in patients with metastatic pancreatic cancer (mPC)…”
Get full text

Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study by Bergen, Elisabeth S., Pilla, Lorenzo, Auclin, Edouard, Ilhan-Mutlu, Aysegül, Prager, Gerald W., Pietrantonio, Filippo, Antista, Maria, Ghelardi, Filippo, Basile, Debora, Aprile, Giuseppe, Longarini, Raffaella, Hautefeuille, Vincent, Tougeron, David, Artru, Pascal, Mabro, May, Drouillard, Antoine, Roth, Gael, Ben Abdelghani, Meher, Clement, Inès, Toullec, Clemence, Mineur, Laurent, Guimbaud, Rosine, Taieb, Julien, Zaanan, Aziz

“…Background The optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma (OGA) remains challenging…”
Get full text

Characteristics of BRAFV600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients by Fouchardière, Christelle, Cohen, Romain, Malka, David, Guimbaud, Rosine, Bourien, Héloïse, Lièvre, Astrid, Cacheux, Wulfran, Artru, Pascal, François, Eric, Gilabert, Marine, Samalin‐Scalzi, Emmanuelle, Zaanan, Aziz, Hautefeuille, Vincent, Rousseau, Benoit, Senellart, Hélène, Coriat, Romain, Flippot, Ronan, Desseigne, Françoise, Lardy‐Cleaud, Audrey, Tougeron, David

“…Background BRAFV600E mutations occurring in about 10% of metastatic colorectal cancers (mCRCs) are usually associated with a poor outcome. However, their…”
Get full text

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort by Manfredi, Sylvain, Dior, Marie, Bouche, Olivier, Barbier, Emilie, Hautefeuille, Vincent, Guillet, Marielle, Turpin, Justine, Bourgeois, Vincent, Helene, Dall Osto, Desgrippes, Romain, Audemar, Franck, Molin, Yann, Locher, Christophe, Chatellier, Thierry, Lecomte, Thierry, Baize, Nathalie, Lecaille, Cedric, Spaeth, Dominique, Goujon, Gael, Lepage, Come, Tougeron, David

“…Background Around 50% of gastric cancers are diagnosed at an advanced stage. Several chemotherapy regimens are now internationally validated. Few data are…”
Get full text

337 Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI by Tougeron, David, Emile, Jean Francois, Kim, Stephano, Monterymard, Carole, Gilabert, Marine, Jérémie, BEZ, Lievre, Astrid, Dahan, Laetitia, Laurent-puig, Pierre, Mineur, Laurent, Coriat, ROmain, Legoux, Jean Louis, Hautefeuille, Vincent, Phelip, Jean marc, Lecomte, Thierry, Sokol, Harry, Capron, Claude, Gallois, Claire, Randrian, Violaine, Lepage, Come, Taieb, Julien

“…BackgroundImmune checkpoint inhibitors (ICI) are very effective in deficient DNA mismatch-repair system (dMMR)/microsatellite instable (MSI) metastatic…”
Get full text

A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics by Nguyen-Khac, Eric, Lobry, Céline, Chatelain, Denis, Fuks, David, Joly, Jean Paul, Brevet, Marie, Tramier, Blaise, Mouly, Charlotte, Hautefeuille, Vincent, Chauffert, Bruno, Regimbeau, Jean Marc

“…Background and Aims. Chemotherapy of colorectal liver metastases can induce hepatotoxicity in noncancerous liver. We describe these lesions and assess risk…”
Get full text

1142 TRANSMURAL HEALING IS NOT ASSOCIATED WITH LESS DISABILITY THAN COMPLETE ENDOSCOPIC MUCOSAL HEALING: A PROSPECTIVE STUDY IN A PATIENT WITH CROHN'S DISEASE by Yzet, Clara, Brazier, Franck, Hautefeuille, Vincent, Grados, Lucien, Decrombecque, Catherine, Momar, Diouf, Fumery, Mathurin

Get full text

Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort by Taïeb, Julien, Sayah, Lina, Heinrich, Kathrin, Kunzmann, Volker, Boileve, Alice, Cirkel, Geert, Lonardi, Sara, Chibaudel, Benoist, Turpin, Anthony, Beller, Tamar, Hautefeuille, Vincent, Vivaldi, Caterina, Mazard, Thibault, Bauguion, Lucile, Niger, Monica, Prager, Gerald W., Coutzac, Clelia, Benedikt Westphalen, C., Auclin, Edouard, Pilla, Lorenzo

“…Immune checkpoint inhibitors (ICIs) improve oncological outcomes in patients with microsatellite instability-high (MSI) or mismatch repair-deficient (dMMR)…”
Get full text

Intestinal Ultrasound, Fecal Calprotectin, and Their Combination to Predict Endoscopic Mucosal Healing in Ulcerative Colitis: A Real-Life Cross-Sectional Study by Yzet, Clara, Meudjo, Erica, Brazier, Franck, Hautefeuille, Vincent, Moreau, Capucine, Robert, Camille, Decrombecque, Catherine, Sarba, Ruxandra, Pichois, Raphael, Richard, Nicolas, Meynier, Jonathan, Fumery, Mathurin

“…The development of noninvasive markers to assess mucosal healing in ulcerative colitis (UC) is essential in the treat-to-target era. The aim of this study was…”
Get full text

Mo1742 ULTRASOUND IS EFFECTIVE TO IDENTIFY MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS : RESULTS OF A CROSS-SECTIONAL STUDY by Yzet, Clara, Brazier, Franck, Hautefeuille, Vincent, Decrombecque, Catherine, Sarba, Ruxandra, Aygalenq, Philippe, Venezia, Franck, Buisson, Anthony, Pichois, Raphael, Michaud, Audrey, Fumery, Mathurin

Get full text

Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study by Tougeron, David, Sueur, Benjamin, Zaanan, Aziz, Fouchardiére, Christelle, Sefrioui, David, Lecomte, Thierry, Aparicio, Thomas, Des Guetz, Gaetan, Artru, Pascal, Hautefeuille, Vincent, Coriat, Romain, Moulin, Valerie, Locher, Christophe, Touchefeu, Yann, Lecaille, Cedric, Goujon, Gael, Ferru, Aurélie, Evrard, Camille, Chautard, Romain, Gentilhomme, Lucie, Vernerey, Dewi, Taieb, Julien, André, Thierry, Henriques, Julie, Cohen, Romain

“…Mismatch repair‐deficient (dMMR) and/or microsatellite instability‐high (MSI) colorectal cancers (CRC) represent about 5% of metastatic CRC (mCRC). Prognosis…”
Get full text

Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO) by Landi, Bruno, Blay, Jean-Yves, Bonvalot, Sylvie, Brasseur, Mathilde, Coindre, Jean Michel, Emile, Jean François, Hautefeuille, Vincent, Honore, Charles, Lartigau, Eric, Mantion, Georges, Pracht, Marc, Le Cesne, Axel, Ducreux, Michel, Bouche, Olivier

“…This document is a summary of the French Intergroup guidelines regarding the management of gastrointestinal stromal tumours (GISTs) updated in December 2018…”
Get full text

Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial by Walter, Thomas, Lievre, Astrid, Coriat, Romain, Malka, David, Elhajbi, Farid, Di Fiore, Fréderic, Hentic, Olivia, Smith, Denis, Hautefeuille, Vincent, Roquin, Guillaume, Perrier, Marine, Dahan, Laetitia, Granger, Victoire, Sobhani, Iradj, Mineur, Laurent, Niccoli, Patricia, Assenat, Eric, Scoazec, Jean-Yves, Le Malicot, Karine, Lepage, Côme, Lombard-Bohas, Catherine

“…There is no standard second-line treatment after platinum–etoposide chemotherapy for gastroenteropancreatic neuroendocrine carcinoma. We aimed to evaluate the…”
Get full text

A randomized noncomparative phase II study of maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM–PRODIGE 63 GERCOR D17-01 study) by Neuzillet, Cindy, Hautefeuille, Vincent, Lambert, Aurélien, Garcia-Larnicol, Marie-Line, Vernerey, Dewi

“…Abstract only TPS4160 Background: FOLFIRINOX (5-fluorouracil [5FU], folinic acid [FA], irinotecan [Iri], and oxaliplatin [Ox]) is a standard 1 st -line…”
Get full text

Plasmatic and Urinary 5-Hydroxyindolacetic Acid Measurements in Patients With Midgut Neuroendocrine Tumors: A GTE Study by de Mestier, Louis, Savagner, Frédérique, Brixi, Hedia, Do Cao, Christine, Dominguez-Tinajero, Sophie, Roquin, Guillaume, Goichot, Bernard, Hentic, Olivia, Dubreuil, Olivier, Hautefeuille, Vincent, Walter, Thomas, Cadiot, Guillaume

“…Abstract Context Although 24-hour urinary 5-hydroxyindolacetic acid (24u5HIAA) is a key biomarker in midgut neuroendocrine tumors (NETs), it may be inaccurate…”
Get full text